BACKGROUND FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem+ nabPTX) were
recently introduced for metastatic pancreatic cancer treatment. However, studies that …

Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-
line treatments in patients with metastatic pancreatic cancer (mPC). However, data …

Objective: By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the
clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in …

Purpose Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX, FFX) and
gemcitabine plus nab-paclitaxel (GnP) are considered standard treatments for patients with …

Purpose nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX have been established as
standard first-line treatment in metastatic pancreatic cancer (mPC). We performed …

Purpose New chemotherapies have become available for the treatment of advanced
pancreatic cancer and have led to changes in its standard treatments. Since pancreatic …

Simple Summary Metastatic PC often represents a complex decision-making moment for
oncologists, particularly due to the general conditions of the patients, age, and the potential …

Abstract Background FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have
been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC) …

Pancreas cancer (PCa) is one of the mortal cancer types with ranking as fourth leading
cancer death in both sexes together. FOLFIRINOX (FFX) and Gemcitabine plus nab …

Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …